Form 4: Travere Therapeutics Executive Sells Shares Under 10b5-1 Plan

A Travere Therapeutics executive, William E. Rote, sold 2,437 shares of common stock at $19.46 per share under a pre-arranged 10b5-1 trading plan.

Summary

• William E. Rote, Senior Vice President of R&D at Travere Therapeutics, sold 2,437 shares of common stock on January 22, 2025.
• The sale was executed at a price of $19.46 per share.
• This transaction was conducted under a pre-arranged trading plan, specifically a 10b5-1 plan, adopted on March 15, 2024.
• The sale included shares to cover tax obligations from the vesting of restricted stock units.
• Following the transaction, Mr. Rote beneficially owns 83,170 shares of Travere Therapeutics common stock.
• This total includes 1,152 shares acquired through the company's 2017 Employee Stock Purchase Plan on November 29, 2024.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged trading plan, with no indication of positive or negative sentiment. It is a neutral event.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, potentially impacting the stock price.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies, often part of pre-planned strategies for personal financial management and diversification. The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology and pharmaceutical sectors, such as Amgen, Gilead Sciences, and Biogen.
• These plans allow executives to sell shares at predetermined times and prices, mitigating the risk of insider trading allegations.
• The volume of shares sold by Mr. Rote is relatively small compared to the total outstanding shares of Travere Therapeutics, and is not unusual for an executive at his level.

Stakeholder Impact

• The sale of shares by an executive may have a minor impact on shareholder sentiment, but is unlikely to have a significant effect on the company's operations or financial health.

Key Dates

Keywords

Travere Therapeutics, insider trading, Form 4, stock sale, 10b5-1 plan, executive, William E. Rote, TVTX, employee stock purchase plan